<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37666572</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>06</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">2053-8790</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Lupus science &amp; medicine</Title><ISOAbbreviation>Lupus Sci Med</ISOAbbreviation></Journal><ArticleTitle>Serum interferon-alpha predicts in-hospital mortality in patients hospitalised with acute severe lupus.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e000933</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/lupus-2023-000933</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Dysregulation of interferon-alpha (IFN-&#x3b1;) is considered central to the immunological abnormalities observed in SLE. Short-term mortality during high disease activity in lupus is up to 30%. Adenovirus vector-introduced IFN-&#x3b1; into a lupus-prone mouse causes the development of glomerulonephritis and death within weeks. We studied serum IFN-&#x3b1; as a biomarker of in-hospital mortality in patients of SLE with high disease activity.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Serum IFN-&#x3b1; (ELISA) was measured in patients hospitalised for acute severe lupus in a tertiary care rheumatology unit in India and the levels were compared between survivors and non-survivors. Serum IFN-&#x3b1; was compared with traditional clinical and serological markers associated with disease activity to assess which better prognosticates survival.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In a cohort of 90 patients with a mean Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) of 19.3 (&#xb1;5.5), the mean serum IFN-&#x3b1; was 88&#xb1;144&#x2009;pg/dL. Levels were undetectable in patients with inactive disease. SLEDAI, anti double stranded DNA (dsDNA) antibody titres and serum IFN-&#x3b1; levels were higher and serum complement (C3) lower in non-survivors (p=0.003, p=0.017, p&lt;0.001, p=0.029, respectively). Serum IFN-&#x3b1; level of 140&#x2009;pg/mL had a sensitivity of 86.7%, specificity of 94.6%, positive predictive value of 76% and negative predictive value of 83.3% (p&lt;0.001) in predicting mortality. The area under the curve for predicting in-hospital mortality was 0.25 for C3, 0.72 for dsDNA, 0.77 for SLEDAI and 0.92 for serum IFN-&#x3b1;.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Serum IFN-&#x3b1; was better in predicting in-hospital mortality compared with conventional measures of disease activity such as anti-dsDNA, complements and SLEDAI.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yerram</LastName><ForeName>Keerthi Vardhan</ForeName><Initials>KV</Initials><AffiliationInfo><Affiliation>Clinical Immunology and Rheumatology, Nizam's Institute of Medical Sciences, Hyderabad, Telangana, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baisya</LastName><ForeName>Ritasman</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-3241-0229</Identifier><AffiliationInfo><Affiliation>Clinical Immunology and Rheumatology, Nizam's Institute of Medical Sciences, Hyderabad, Telangana, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Phani</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Clinical Immunology and Rheumatology, Nizam's Institute of Medical Sciences, Hyderabad, Telangana, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mylavarapu</LastName><ForeName>Rammohan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Microbiology, Nizam's Institute of Medical Sciences, Hyderabad, Telangana, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rajasekhar</LastName><ForeName>Liza</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-9789-9985</Identifier><AffiliationInfo><Affiliation>Rheumatology, Nizam's Institute of Medical Sciences, Hyderabad, Telangana, India lizarajasekhar@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lupus Sci Med</MedlineTA><NlmUniqueID>101633705</NlmUniqueID><ISSNLinking>2053-8790</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016898">Interferon-alpha</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017052" MajorTopicYN="N">Hospital Mortality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016898" MajorTopicYN="N">Interferon-alpha</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005921" MajorTopicYN="Y">Glomerulonephritis</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Lupus Erythematosus, Systemic</Keyword><Keyword MajorTopicYN="N">Outcome Assessment, Health Care</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>6</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>5</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>4</Day><Hour>20</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37666572</ArticleId><ArticleId IdType="pmc">PMC10481835</ArticleId><ArticleId IdType="doi">10.1136/lupus-2023-000933</ArticleId><ArticleId IdType="pii">10/2/e000933</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ytterberg SR, Schnitzer TJ. Serum interferon levels in patients with systemic lupus erythematosus. Arthritis Rheum 1982;25:401&#x2013;6. 10.1002/art.1780250407</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780250407</ArticleId><ArticleId IdType="pubmed">6176248</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett L, Palucka AK, Arce E, et al. . Interferon and Granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003;197:711&#x2013;23. 10.1084/jem.20021553</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20021553</ArticleId><ArticleId IdType="pmc">PMC2193846</ArticleId><ArticleId IdType="pubmed">12642603</ArticleId></ArticleIdList></Reference><Reference><Citation>Baechler EC, Batliwalla FM, Karypis G, et al. . Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A 2003;100:2610&#x2013;5. 10.1073/pnas.0337679100</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0337679100</ArticleId><ArticleId IdType="pmc">PMC151388</ArticleId><ArticleId IdType="pubmed">12604793</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiche L, Jourde-Chiche N, Whalen E, et al. . Modular transcriptional repertoire analyses of adults with systemic lupus erythematosus reveal distinct type I and type II interferon signatures. Arthritis Rheumatol 2014;66:1583&#x2013;95. 10.1002/art.38628</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.38628</ArticleId><ArticleId IdType="pmc">PMC4157826</ArticleId><ArticleId IdType="pubmed">24644022</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan L, Lu M-P, Wang J-H, et al. . Immunological pathogenesis and treatment of systemic lupus erythematosus. World J Pediatr 2020;16:19&#x2013;30. 10.1007/s12519-019-00229-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12519-019-00229-3</ArticleId><ArticleId IdType="pmc">PMC7040062</ArticleId><ArticleId IdType="pubmed">30796732</ArticleId></ArticleIdList></Reference><Reference><Citation>Banchereau J, Pascual V. Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 2006;25:383&#x2013;92. 10.1016/j.immuni.2006.08.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2006.08.010</ArticleId><ArticleId IdType="pubmed">16979570</ArticleId></ArticleIdList></Reference><Reference><Citation>Zonana-Nacach A, Ya&#xf1;ez P, Jim&#xe9;nez-Balderas FJ, et al. . Disease activity, damage and survival in Mexican patients with acute severe systemic lupus erythematosus. Lupus 2007;16:997&#x2013;1000. 10.1177/0961203307083175</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203307083175</ArticleId><ArticleId IdType="pubmed">18042596</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma A, Shamanna SB, Kumar S, et al. . Causes of mortality among inpatients with systemic lupus erythematosus in a tertiary care hospital in North India over a 10-year period. Lupus 2013;22:216&#x2013;22. 10.1177/0961203312468626</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203312468626</ArticleId><ArticleId IdType="pubmed">23192325</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M, Orbai A-M, Alarc&#xf3;n GS, et al. . Derivation and validation of the systemic lupus International collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012;64:2677&#x2013;86. 10.1002/art.34473</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.34473</ArticleId><ArticleId IdType="pmc">PMC3409311</ArticleId><ArticleId IdType="pubmed">22553077</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochberg MC. Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40. 10.1002/art.1780400928</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780400928</ArticleId><ArticleId IdType="pubmed">9324032</ArticleId></ArticleIdList></Reference><Reference><Citation>Arora S, Isenberg DA, Castrejon I. Measures of adult systemic lupus erythematosus: disease activity and damage. Arthritis Care Res (Hoboken) 2020;72:27&#x2013;46. 10.1002/acr.24221</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.24221</ArticleId><ArticleId IdType="pubmed">33091256</ArticleId></ArticleIdList></Reference><Reference><Citation>Yee C-S, Cresswell L, Farewell V, et al. . Numerical scoring for the BILAG-2004 index. Rheumatology (Oxford) 2010;49:1665&#x2013;9. 10.1093/rheumatology/keq026</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keq026</ArticleId><ArticleId IdType="pmc">PMC2919194</ArticleId><ArticleId IdType="pubmed">20181671</ArticleId></ArticleIdList></Reference><Reference><Citation>Su&#xe1;rez-Avellaneda A, Quintana JH, Arag&#xf3;n CC, et al. . Systemic lupus erythematosus in the intensive care unit: a systematic review. Lupus 2020;29:1364&#x2013;76. 10.1177/0961203320941941</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203320941941</ArticleId><ArticleId IdType="pubmed">32723062</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo J, Huang Z, Huang M, et al. . Development of a novel simple model to predict mortality in patients with systemic lupus erythematosus admitted to the intensive care unit. Front Med (Lausanne) 2021;8. 10.3389/fmed.2021.689871</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.689871</ArticleId><ArticleId IdType="pmc">PMC8339434</ArticleId><ArticleId IdType="pubmed">34368189</ArticleId></ArticleIdList></Reference><Reference><Citation>Kavadichanda C, Ganapathy S, Kounassegarane D, et al. . Clusters based on demography, disease phenotype, and autoantibody status predicts mortality in lupus: data from Indian lupus cohort (INSPIRE). Rheumatology (Oxford) 2023. 10.1093/rheumatology/kead148</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kead148</ArticleId><ArticleId IdType="pubmed">37018148</ArticleId></ArticleIdList></Reference><Reference><Citation>Manadan AM, Kambhatla S, Gauto-Mariotti E, et al. . Reasons for hospitalization and in-hospital mortality in adult systemic lupus erythematosus. ACR Open Rheumatol 2020;2:683&#x2013;9. 10.1002/acr2.11195</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr2.11195</ArticleId><ArticleId IdType="pmc">PMC7672299</ArticleId><ArticleId IdType="pubmed">33164350</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno-Torres V, Tar&#xed;n C, Ruiz-Irastorza G, et al. . Trends in hospital admissions and death causes in patients with systemic lupus erythematosus: Spanish national Registry. J Clin Med 2021;10. 10.3390/jcm10245749</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10245749</ArticleId><ArticleId IdType="pmc">PMC8707218</ArticleId><ArticleId IdType="pubmed">34945045</ArticleId></ArticleIdList></Reference><Reference><Citation>Tselios K, Gladman DD, Sheane BJ, et al. . All-cause, cause-specific and age-specific standardised mortality ratios of patients with systemic lupus erythematosus in Ontario, Canada over 43 years (1971-2013). Ann Rheum Dis 2019;78:802&#x2013;6. 10.1136/annrheumdis-2018-214802</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2018-214802</ArticleId><ArticleId IdType="pubmed">30992296</ArticleId></ArticleIdList></Reference><Reference><Citation>Pattanaik SS, Muhammed H, Chatterjee R, et al. . In-hospital mortality and its predictors in a cohort of SLE from northern India. Lupus 2020;29:1971&#x2013;7. 10.1177/0961203320961474</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203320961474</ArticleId><ArticleId IdType="pubmed">32998621</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathian A, Weinberg A, Gallegos M, et al. . IFN-alpha induces early lethal lupus in preautoimmune (New Zealand black X New Zealand white) F1 but not in BALB/C mice. J Immunol 2005;174:2499&#x2013;506. 10.4049/jimmunol.174.5.2499</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.174.5.2499</ArticleId><ArticleId IdType="pubmed">15728455</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathian A, Mouries-Martin S, Dorgham K, et al. . Monitoring disease activity in systemic lupus erythematosus with single-molecule array Digital enzyme-linked immunosorbent assay Quantification of serum interferon-&#x391;. Arthritis Rheumatol 2019;71:756&#x2013;65. 10.1002/art.40792</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40792</ArticleId><ArticleId IdType="pubmed">30507062</ArticleId></ArticleIdList></Reference><Reference><Citation>Dall&#x2019;era MC, Cardarelli PM, Preston BT, et al. . Type I interferon correlates with serological and clinical manifestations of SLE. Ann Rheum Dis 2005;64:1692&#x2013;7. 10.1136/ard.2004.033753</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2004.033753</ArticleId><ArticleId IdType="pmc">PMC1755300</ArticleId><ArticleId IdType="pubmed">15843451</ArticleId></ArticleIdList></Reference><Reference><Citation>Oke V, Gunnarsson I, Dorschner J, et al. . High levels of circulating Interferons type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosus. Arthritis Res Ther 2019;21. 10.1186/s13075-019-1878-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-019-1878-y</ArticleId><ArticleId IdType="pmc">PMC6489203</ArticleId><ArticleId IdType="pubmed">31036046</ArticleId></ArticleIdList></Reference><Reference><Citation>Bengtsson AA, Sturfelt G, Truedsson L, et al. . Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus 2000;9:664&#x2013;71. 10.1191/096120300674499064</Citation><ArticleIdList><ArticleId IdType="doi">10.1191/096120300674499064</ArticleId><ArticleId IdType="pubmed">11199920</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>